Hematopoietic stem cell gene therapy: selecting only the best
AUTOR(ES)
Bank, Arthur
FONTE
American Society for Clinical Investigation
RESUMO
Hematopoietic stem cell (HSC) gene therapy can potentially cure a variety of human hematopoietic diseases, such as sickle cell disease. Selection and expansion of gene-corrected HSCs has now been accomplished for the first time using HSC from large animals — dogs and humans — with a novel drug-resistance gene, MGMT, which is not expressed in normal HSCs (see the related articles beginning on pages 1561 and 1581). Highly efficient lentiviral transfer and expression of MGMT into relatively few HSCs led to repopulation of most of the hematopoietic compartment with gene-corrected cells following suitable drug treatment. This selection system may be useful in human clinical trials to permit gene therapy in autologous and allogeneic bone marrow transplantation settings.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=259135Documentos Relacionados
- Epigenetic therapy in allogeneic hematopoietic stem cell transplantation
- One strategy for cell and gene therapy: Harnessing the power of adult stem cells to repair tissues
- An X chromosome gene regulates hematopoietic stem cell kinetics
- Gene Therapy: Fighting against the Next Plateau
- Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: The case for
